Lunit and Agilent Partner to Develop AI-Powered Cancer Diagnostics

Biomarker testing plays a critical role in precision oncology, guiding tailored therapies for patients. However, current methods often rely heavily on manual interpretation, which can introduce variability and delay decision-making. With the growing demand for novel and complex biomarker assays, there is an urgent need for advanced solutions that can improve accuracy, efficiency, and scalability in diagnostics. Now, a new collaboration combines expertise in artificial intelligence (AI) with diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities.

Lunit (Seoul, South Korea) and Agilent Technologies (Santa Clara, CA, USA) have entered into a nonexclusive collaboration to develop AI-based companion diagnostic solutions. The collaboration will leverage Lunit's AI technology and Agilent's expertise in tissue-based companion diagnostics to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development.

Image: Lunit and Agilent Technologies are collaborating to develop AI-powered companion diagnostics. (Photo courtesy of Lunit)

Under this agreement, Lunit and Agilent will develop advanced AI-powered companion diagnostic tools designed to enhance the accuracy of diagnosis and the measurement of therapeutic efficacy. The initial focus will be on leveraging Lunit's AI algorithms with Agilent's state-of-the-art assays to evaluate biomarkers critical for the development of new pharmaceutical therapies.

The joint solutions will support pharmaceutical companies in companion diagnostic (CDx) product development, improving the precision and accuracy of biomarker testing, and ultimately benefiting patients with more tailored treatment options. The collaboration will initially focus on the co-development of AI-powered assays for use in research and clinical trials. This agreement marks a significant step forward for both companies as they seek to redefine the role of artificial intelligence in precision oncology and translational medicine.

"Biomarker testing is at the heart of precision oncology, but today it is still largely dependent on manual interpretation," said Brandon Suh, CEO of Lunit. "By combining Agilent's global leadership in tissue-based diagnostics with Lunit's proven AI algorithms, we can help pharma partners bring biomarker-driven therapies to market faster and with greater confidence - ultimately ensuring patients receive the right treatment at the right time."

"Agilent is committed to bringing cutting-edge diagnostic solutions to our pharmaceutical partners and ultimately to patients, and this collaboration with Lunit further strengthens our ability to offer the most advanced companion diagnostic solutions available today," added Nina Green, vice-president and general manager of Agilent's Clinical Diagnostics Division at Agilent. "Through this collaboration with Lunit, we aim to deliver next-generation diagnostic tools that enable the advancement of precision medicine worldwide."

Related Links:
Lunit
Agilent Technologies